Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

XBIT

XBiotech (XBIT)

XBiotech Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:XBIT
DateTimeSourceHeadlineSymbolCompany
06/20/202412:57PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XBITXBiotech Inc
06/18/202411:35AMGlobeNewswire Inc.XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic CancerNASDAQ:XBITXBiotech Inc
05/10/202411:27AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XBITXBiotech Inc
02/07/202412:36PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:XBITXBiotech Inc
02/07/202412:01PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:XBITXBiotech Inc
01/05/202410:48AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XBITXBiotech Inc
01/04/20249:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XBITXBiotech Inc
01/04/20249:00AMGlobeNewswire Inc.XBiotech to Begin Constructing New R&D Facility on its 48-acre CampusNASDAQ:XBITXBiotech Inc
01/04/20249:00AMGlobeNewswire Inc.XBiotech to Begin Constructing New R&D Facility on its 48-acre CampusNASDAQ:XBITXBiotech Inc
11/14/20239:00AMGlobeNewswire Inc.Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid ArthritisNASDAQ:XBITXBiotech Inc
11/09/20232:41PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XBITXBiotech Inc
09/26/20239:00AMGlobeNewswire Inc.XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeNASDAQ:XBITXBiotech Inc
08/30/20239:00AMGlobeNewswire Inc.XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic CancerNASDAQ:XBITXBiotech Inc
08/11/202311:18AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XBITXBiotech Inc
08/08/202311:47AMGlobeNewswire Inc.XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical TrialNASDAQ:XBITXBiotech Inc
06/26/20238:48AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XBITXBiotech Inc
06/26/20238:46AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XBITXBiotech Inc
06/26/20238:43AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XBITXBiotech Inc
06/26/20238:40AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XBITXBiotech Inc
06/23/20233:04PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XBITXBiotech Inc
06/20/20239:20AMEdgar (US Regulatory)Amended Tender Offer Statement by Issuer (sc To-i/a)NASDAQ:XBITXBiotech Inc
05/22/20239:00AMGlobeNewswire Inc.FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsNASDAQ:XBITXBiotech Inc
05/17/20239:22AMEdgar (US Regulatory)Tender Offer Statement by Issuer (sc To-i)NASDAQ:XBITXBiotech Inc
05/17/20239:00AMGlobeNewswire Inc.XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesNASDAQ:XBITXBiotech Inc
05/10/20233:42PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:XBITXBiotech Inc
04/28/202312:38PMEdgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:XBITXBiotech Inc
04/28/202312:33PMEdgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:XBITXBiotech Inc
02/15/20236:12AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XBITXBiotech Inc
02/10/202312:22PMEdgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:XBITXBiotech Inc
02/10/202312:21PMEdgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:XBITXBiotech Inc
 Showing the most relevant articles for your search:NASDAQ:XBIT